Healing & Recovery

Pentadeca arginate

PDA · BPC-157 arginate · BPC-157 arginine salt · pentadecapeptide arginate

Arginine salt of BPC-157 (the same 15-aa gastric peptide), sold as a distinct SKU from BPC-157 acetate. Vendors claim better oral/gastric stability. There is no separate human PK package for the arginate salt - treat identity as BPC-157 with a different counterion. FDA Category 2 applies to the peptide, not the salt name.

Not FDA-approved - research chemicalWADA (S0) - prohibited in sport at all timesContains FDA Category 2 material (BPC-157). PCAC Jul 2026 review is advisory, not a final rule

Quick answer

What it is: Arginine salt of BPC-157 (the same 15-aa gastric peptide), sold as a distinct SKU from BPC-157 acetate.

Typical research dose: 250-500 mcg/day (injectable) or vendor oral protocols (salt marketed for GI stability)

Reconstitution calculator ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Strong preclinical·1 peer-reviewed citation

Typical research dose

250-500 mcg/day (injectable) or vendor oral protocols (salt marketed for GI stability)

Frequency

1-2× daily

Half-life

Not published for the salt; BPC IV PK is minutes

Common vials

5 mg / 10 mg

CAS

N/A (salt)

Molecular weight

~1.4 kDa peptide + arginine

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Injury & tissue5/10
Same 15-mer as BPC-157 acetate. Score tracks the parent leaf. Salt-specific human data does not exist, so this is not a second, higher score.
Recovery & sleep4/10
Sold into the same recovery-protocol slot as acetate BPC. Not a sleep peptide.

Compound card

Sequence: GEPPPGKPADDAGLV (arginine salt)
Class: BPC-157 arginine salt (not a new INN)
Formula: BPC-157 arginine salt
Status: Not FDA-approved · research use

Dose it

5 mg + 2 mL BAC water → 2.5 mg/mL · 250 mcg ≈ 10 units (U-100)

Open in calculator

How it works

Pentadeca arginate is BPC-157 as the arginine salt instead of acetate. Sequence is the same pentadecapeptide. Oral-stability claims are formulation marketing. Published animal PK and repair papers are almost entirely BPC-157 acetate or free peptide. FDA Category 2 follows the peptide, not the salt name. If the question is mechanism or PK, read the BPC-157 leaf.

Source: BPC-157: PMID: 30915550. Arginate salt: vendor chemistry, not a separate INN.

Same peptide as BPC-157

If your question is mechanism or Category 2 status, use the BPC-157 leaf. This page exists because vendors sell PDA as a separate SKU (often oral). Do not double-count it as a new INN.

Goal context

Why this leaf exists

Vendors sell PDA as a distinct catalog item, often with oral claims. The sequence is BPC-157. This page is an identity warning, not a second monograph.

Research Use Cases

✓Why this leaf exists

Dosing

Phase	Dose	Frequency	Notes
Injectable (treat as BPC-157)	250–500 mcg/day	1–2× daily	Same research range as acetate BPC.
Oral SKU	Vendor-dependent	Daily	No consensus human oral bioavailability figure we will print as fact.

Administration

Route / form

SC or oral (SKU-dependent)

Timing

As with BPC-157 if injectable.

Empty stomach?

No - Food timing is not critical.

Pentadeca arginate: oral vs SubQ

Injectable arginate vial

Bioavailability

Same 15-mer as BPC-157 acetate. Salt-specific human PK is unpublished. Treat parenteral exposure as the parent peptide until someone publishes otherwise. He 2022 is acetate/free peptide in animals, not this salt.

Dose note

If the bottle is lyophilized: BAC-reconstitute like acetate BPC. Community 250–500 mcg/day. Confirm the COA is injectable, not a capsule. Category 2 follows the peptide, not the salt name.

Advantages

Parenteral identity is BPC-157 with arginine as the counterion. Recon math is legitimate on a cake.
Separates this SKU from oral-only vendor bottles.

Considerations

Not a new INN. Do not double-count animal acetate papers as salt-specific proof.
FDA Category 2 and WADA S0 still apply.

Oral PDA (vendor)

Bioavailability

Oral-stability ads are why this SKU exists. There is no dedicated human oral PK package for the arginate salt. Do not print an F%. Parent acetate oral Phase 1 (NCT02637284) posted no results either.

Dose note

Capsules are swallowed. Do not force oral product into the reconstitution calculator. Vendor milligrams are not 250 mcg SC. Timing folklore is not a label.

Advantages

This is the catalog reason people search “PDA” instead of BPC-157.
No BAC water if the SKU is actually a capsule.

Considerations

Formulation marketing is not a second evidence base.
Same peptide, same Category 2 problem, same missing human RCT.

Recommendation: PDA is BPC-157 as the arginine salt. Injectable cakes get BAC math. Oral bottles are the vendor pitch, not a published F%. Read the BPC-157 leaf for mechanism and PK. Salt name is not a new drug.

Timeline

As BPC-157

Do not invent a faster oral timeline.

Who it is for

BPC-157 salt SKU

Low

Catalog differentiation. Evidence is the parent peptide.

Reconstitution

Vial	Water	Concentration	Example dose
5 mg (injectable SKU)	2.0 mL BAC	2.5 mg/mL	250 mcg = 0.10 mL = 10 units. Confirm the bottle is injectable, not an oral capsule.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Same caveats as BPC-157: research-only, Category 2, angiogenic theoretical risk. Salt change is not a safety database.

Regulatory & Legal Status

FDA Status (US)

Research Only

Arginine salt of BPC-157 - same FDA Category 2 peptide, different counterion

WADA Status (2026)

Prohibited (S0)

Competitive athletes subject to anti-doping controls should not use Pentadeca arginate.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

No dedicated human PK package for the arginate salt.
Animal repair literature is almost entirely acetate or free BPC-157.
Oral SKUs do not inherit SubQ recon math. Check the label for route.

Verdict

PDA is a salt SKU, not a new peptide. Use it when that is what is in the bottle. Do not treat oral-stability ads as a second PK package. Mechanism, Category 2, and WADA S0 are the BPC-157 story.

Interactions & Contraindications

Same caveats as BPC-157: research-only, Category 2, angiogenic theoretical risk. Salt change is not a safety database.

Pentadeca arginate vs. BPC-157

Canonical comparison: Pentadeca arginate vs BPC-157

Attribute	Pentadeca arginate	BPC-157
Identity	Arginine salt of the same 15-aa peptide	Acetate / free pentadecapeptide in most papers
FDA	Category 2 peptide (same molecule)	Category 2
Oral claims	Marketed for GI stability	Also used oral in community; gastric origin is the story
PK	Salt-specific human PK unpublished	IV animal PK is minutes - not 4 hours

Verdict: PDA is BPC-157 with a different counterion. Do not treat it as a new INN.

Frequently Asked Questions

Oral PDA or injectable?▼

If the bottle is a lyophilized cake, treat it as BPC-157 and recon with BAC water. If it is a capsule, swallow it and skip the calculator. Oral-stability ads are not a published human PK package. Same 15-mer, same Category 2 problem.

Is PDA stronger than BPC-157?▼

It is BPC-157 with arginine as the counterion. Strength claims beyond acetate are not a second evidence base.

Can I put oral PDA in the reconstitution calculator?▼

Only if the SKU is a lyophilized injectable vial. Capsules are swallowed. Do not force oral product into SubQ math.

Does Category 2 still apply?▼

Yes. The FDA bulk-substance concern is the peptide, not the salt name.

References

He L, Feng D, Guo H, et al. “Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157 in rats and dogs.” Frontiers in Pharmacology (2022). PMID: 36588717

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library